We, as Janssen, are committed to improving healthcare. We recognize the challenges Europe faces, including the COVID-19 pandemic, energy crisis, geopolitics, and ageing populations. Investing believe investing in pharmaceutical innovation and prioritizing population health are crucial for overcoming these challenges.
Drug innovation has not only allowed for the cure and the prevention of diseases but has also helped to reduce symptoms, increase life expectancy, accelerate recovery time, reduce adverse effects and negative interaction with other drugs, and find new routes of administration that are more comfortable for the patient[8]. Austerity measures can hinder innovation, limit access, and worsen health disparities[9]. Cost-containment policies may lead to short-term savings, but they can stifle the development of innovative medicines that have the potential for long-term cost reductions[10]. Therefore, we advocate for policies that foster research and ensure patient access to treatments.
We believe by implementing value-based agreements we can harmonize sustainability with incentives for innovation, creating a healthcare environment that supports individual patients, society, and national economies. Together, we can shape a future that prioritizes patients, supports sustainable healthcare systems, and fosters pharmaceutical innovation for a healthier tomorrow.